---
title: 'Efficacy and safety of gene therapy with onasemnogene abeparvovec in children
  with spinal muscular atrophy in the D-A-CH-region: a population-based observational
  study'
date: '2024-10-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39434961/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241022193450&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Real-world data on gene addition therapy (GAT) with onasemnogene
  abeparvovec (OA), including all age groups and with or without symptoms of the disease
  before treatment are needed to provide families with evidence-based advice and realistic
  therapeutic goals. Aim of this study is therefore a population-based analysis of
  all patients with SMA treated with OA across Germany, Austria and Switzerland ...'
disable_comments: true
---
BACKGROUND: Real-world data on gene addition therapy (GAT) with onasemnogene abeparvovec (OA), including all age groups and with or without symptoms of the disease before treatment are needed to provide families with evidence-based advice and realistic therapeutic goals. Aim of this study is therefore a population-based analysis of all patients with SMA treated with OA across Germany, Austria and Switzerland ...